Jan 8, 2026
An HCRN study, HCRN-GI23-617, will be presented as a Trials in Progress poster at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 in San Francisco. This study is led by Tiago Biachi de Castria, MD, PHD, of H. Lee Moffitt Cancer Center and Research Institute.
- Session Details: Poster Session B, on January 9, 11:30 am – 1:00 pm
- Presentation Title: Phase II study of NALIRIFOX (nanoliposomal irinotecan + oxaliplatin with fluorouracil and folinic acid) in advanced unresectable small bowel tumors
- Abstract: TPS802
- Poster Board: N10
This is a phase II, single-arm, multicenter study evaluating NALIRIFOX in patients with advanced unresectable or metastatic small bowel adenocarcinoma, a rare gastrointestinal malignancy with limited standard first-line treatment options. The study is designed to assess overall response rate using a two-stage Bayesian predictive probability model, with secondary endpoints including safety, duration of response, progression-free survival, and overall survival.
NALIRIFOX combines nanoliposomal irinotecan with oxaliplatin, fluorouracil, and folinic acid. The regimen has demonstrated improved outcomes in other gastrointestinal cancers and is being investigated here to better define its activity in small bowel adenocarcinoma. The trial plans to enroll up to 36 participants.
See abstract: https://www.asco.org/abstracts-presentations/255937
Learn more: https://hoosiercancer.org/all-clinical-trials/hcrn-gi23-617/
JOIN AN HCRN CLINICAL TRIAL WORKING GROUP
Hoosier Cancer Research Network invites investigators from our member institutions to participate in Clinical Trial Working Groups. Through regular teleconferences and occasional in-person meetings, the group remains active throughout the lifetime of HCRN studies. Fostering an environment of mentorship, these groups are ideal for physicians at all levels in both academic and community settings. CTWGs provide investigators with opportunities to: evaluate concepts during the development and design of a protocol; receive input on concepts from key opinion leaders; co-author publications; share best practices in clinical oncology; and meet with funders to discuss areas of interest and concept submission guidelines. Researchers interested in contributing to these efforts are invited to join a working group here.
ABOUT HOOSIER CANCER RESEARCH NETWORK
Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis.
